Abstract
Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 518-526 |
| Number of pages | 9 |
| Journal | European Journal of Cancer |
| Volume | 48 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2012 Mar 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer. / Kim, Gun Min; Jeung, Hei Cheul; Rha, Sun Young; Kim, Hyo Song; Jung, Inkyung; Nam, Byung Ho; Lee, Kyung Hee; Chung, Hyun Cheol.
In: European Journal of Cancer, Vol. 48, No. 4, 01.03.2012, p. 518-526.Research output: Contribution to journal › Article
TY - JOUR
T1 - A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer
AU - Kim, Gun Min
AU - Jeung, Hei Cheul
AU - Rha, Sun Young
AU - Kim, Hyo Song
AU - Jung, Inkyung
AU - Nam, Byung Ho
AU - Lee, Kyung Hee
AU - Chung, Hyun Cheol
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.
AB - Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations. Methods: The patients received S-1 at 80 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the S-1/oxaliplatin (SOX) arm, and capecitabine at 2000 mg/m 2 for 14 days, followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin (CAPOX) arm. Oxaliplatin 130 mg/m 2 was administered every 3 weeks in both arms. Results: One hundred twenty-nine patients were randomly assigned to SOX (N = 65) or CAPOX (N = 64). The median time to progression and the overall survival were 6.2 and 12.4 months with SOX, respectively; and 7.2 and 13.3 months with CAPOX, respectively. The overall response rates were 40% and 44% for SOX and CAPOX, respectively. The most frequent grade 3 or 4 toxicities were thrombocytopenia (15.4%) for SOX and neutropenia (18.8%) for CAPOX. The median time to 10% deteriorations in global health scores was similar in both arms (SOX, 4.3 months, CAPOX, 4.9 months). Conclusion: Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84862820321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862820321&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2011.12.017
DO - 10.1016/j.ejca.2011.12.017
M3 - Article
C2 - 22243774
AN - SCOPUS:84862820321
VL - 48
SP - 518
EP - 526
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 4
ER -